Envestnet Asset Management Divests 106 Shares of Karuna Therapeutics, Inc
December 17, 2023
☀️Trending News
Envestnet Asset Management Inc. recently disposed of 106 shares of Karuna Therapeutics ($NASDAQ:KRTX), Inc., an emerging biopharmaceutical company that is focused on developing novel treatments for cognitive and psychiatric disorders. Karuna Therapeutics aims to bring innovative medicines to patients suffering from schizophrenia, bipolar disorder, and other major neuropsychiatric disorders. The company is developing a pipeline of first-in-class, centrally acting, small molecule therapies targeting key neurotransmitter systems in the brain. Karuna Therapeutics is a publicly traded company on the Nasdaq Global Select Market and is headquartered in Cambridge, Massachusetts. Its shares are traded under the ticker symbol KRTX.
The company has already established collaborations with international pharmaceutical companies and research institutions in order to develop its therapies and accelerate their progress into clinical trials. Karuna’s focus on developing treatments for cognitive and psychiatric disorders is providing a valuable addition to the healthcare landscape and represents an important step forward in the fight against these illnesses. By divesting its shares, Envestnet Asset Management Inc. has demonstrated its commitment to supporting this mission.
Stock Price
This led to the stock of Karuna Therapeutics opening at $189.9 and closing at $185.4, down by 2.9% from the previous closing price of $190.9. This indicates that the stock has not been performing well since the divestment and could be an area of concern for investors. It remains to be seen whether the stock will pick up in the near future or continue to decline. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Karuna Therapeutics. More…
| Total Revenues | Net Income | Net Margin |
| 5.93 | -396.07 | -6676.8% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Karuna Therapeutics. More…
| Operations | Investing | Financing |
| -353.52 | -559.38 | 468.89 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Karuna Therapeutics. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.39k | 62.78 | 35.1 |
Key Ratios Snapshot
Some of the financial key ratios for Karuna Therapeutics are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 0.0% | – | -7589.8% |
| FCF Margin | ROE | ROA |
| -6000.1% | -20.5% | -20.3% |
Analysis
At GoodWhale, we have conducted an in-depth analysis of KARUNA THERAPEUTICS‘s financials. According to our Star Chart, KARUNA THERAPEUTICS has an intermediate health score of 5/10 with regard to its cashflows and debt, suggesting that it is likely to safely ride out any crisis without the risk of bankruptcy. Furthermore, we have classified KARUNA THERAPEUTICS as a ‘rhino’, meaning that the company has achieved moderate revenue or earnings growth. For investors interested in KARUNA THERAPEUTICS, it is important to note that the company is strong in asset and growth, however it is weak in dividend and profitability. Overall, this suggests that KARUNA THERAPEUTICS may be suitable for investors looking for a solid company that has achieved some growth but may not be the best option for investors in search of high dividend yields. More…
Peers
In the race to develop new and improved treatments for a variety of diseases, Karuna Therapeutics Inc is up against some stiff competition. Verona Pharma PLC, Reviva Pharmaceuticals Holdings Inc, and Aptose Biosciences Inc are all working on their own cutting-edge therapies that could one day revolutionize the way we treat illness. While it remains to be seen who will come out on top in this fierce competition, one thing is for sure: the patients who stand to benefit from these breakthroughs are the real winners.
– Verona Pharma PLC ($NASDAQ:VRNA)
Verona Pharma PLC is a clinical stage pharmaceutical company that focuses on the development of drugs for the treatment of respiratory diseases. The company’s lead product, RPL554, is a novel, inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which are key regulators of airway smooth muscle tone. RPL554 is currently in Phase II clinical trials for the treatment of asthma and chronic obstructive pulmonary disease.
Verona Pharma PLC’s market cap as of 2022 is 790.27M. The company’s ROE for the same period is -28.69%.
– Reviva Pharmaceuticals Holdings Inc ($NASDAQ:RVPH)
Reviva Pharmaceuticals Holdings Inc is a holding company that operates through its subsidiaries in the pharmaceutical industry. The company focuses on the development of drugs for the treatment of neurological and psychiatric disorders. It has a market cap of 86.88M as of 2022 and a ROE of -63.24%. The company’s products include drugs for the treatment of Alzheimer’s disease, Parkinson’s disease, and schizophrenia.
– Aptose Biosciences Inc ($TSX:APS)
Aptose Biosciences Inc is a clinical-stage biotechnology company that focuses on the development of personalized therapeutics for the treatment of cancer. The company’s market cap is 71.07M as of 2022 and has a Return on Equity of -59.91%. The company’s focus on developing personalized therapeutics makes it an attractive option for investors interested in the healthcare sector.
Summary
Envestnet Asset Management Inc. recently sold 106 shares of Karuna Therapeutics, Inc. (KARUNA), a biopharmaceutical company focused on developing novel therapies for neurological and psychiatric diseases. Karuna is currently in the process of evaluating potential treatments for schizophrenia, Alzheimer’s disease, and other indications. The company has reported positive results for various clinical studies and continues to gain traction among investors. Analysts believe that the market potential for Karuna’s treatments is large and the company has the potential to become a leader in the biopharmaceutical industry. Financial analysis also reveals that Karuna has a strong balance sheet, with cash reserves that are far greater than its current debt.
The company has made strategic investments in research and development, which will help it continue to develop novel treatments and bring them to market. Overall, Karuna Therapeutics is an exciting investment opportunity, with its stock price increasing steadily over the past several months and its strong balance sheet and innovative pipeline of treatments. Investors should continue to monitor the company’s progress to determine if the stock is a good buy at current levels.
